Publications by authors named "Jacques Rouanet"

Claim this Profile
I
Impact of melanoma histological regression on first-line immunotherapy response in stage-IV disease.
Jean-Baptiste Such, Sandrine Mansard, Mélissa Zlobecki, Carole Chevenet, Céline Lambert, Jacques Rouanet

J Eur Acad Dermatol Venereol· October 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Imatinib-Induced Reactive Angioendotheliomatosis: A Paradoxical Pro-Angiogenic Case.
Elise Lang, Olivier Tournilhac, Carole Chevenet, Aude Clement, Marc G Berger, Jacques Rouanet

Int J Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Targeting Melanin Heterogeneity in Metastatic Melanoma: A Dual-Tumour Mouse Melanoma Model.
Marine Delmas, Benjamin Chaussin, Nathan Harismendy, Aurore Dougé, Paul-Olivier Rouzaire, Jacques Rouanet

Exp Dermatol· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Tc]Tc-NTP 15 - 5, a new proteoglycan tracer for functional imaging of joint cartilage: phase I (CARSPECT).
Marion Chanchou, Emilie Thivat, Sylvain Mathieu, Sophie Levesque, Nicolas Sas, Jacques Rouanet

EJNMMI Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tumor sink effect on melanin-ligand [I]ICF01012 in melanoma and its implications for targeted radionuclide therapy.
Elodie Jouberton, Sophie Besse, Tommy Billoux, Philippe Auzeloux, Sébastien Schmitt, Jacques Rouanet

EJNMMI Res· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Overall Survival After Allogeneic Transplantation in Advanced Cutaneous T-Cell Lymphomas (CUTALLO): A Propensity Score-Matched Controlled Prospective Study.
Adèle de Masson, Marie Beylot-Barry, Caroline Ram-Wolff, Jean-Baptiste Mear, Stéphane Dalle, Jacques Rouanet

J Clin Oncol· August 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Neoadjuvant immune checkpoint inhibitors for patients with resectable stage III/IV melanoma: A nationwide real-life study in France (NEOMEL).
Charlée Nardin, Charlotte Cavalieri, Céleste Lebbé, Emilie Gérard, Marc Puyraveau, Jacques Rouanet

Br J Dermatol· July 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pyoderma gangrenosum-like neutrophilic dermatosis as an adverse effect of menin-KMT2A inhibitor therapy for acute myeloid leukaemia.
Urbain Tauveron-Jalenques, Khadim Sarr, Romain Guièze, Chloé Giordano, Jacques Rouanet

Ann Hematol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Inguinal intertrigo in a patient with aggressive systemic mastocytosis.
Pauline Delamotte, Justine Pasteur, Michel D'Incan, Carole Chevenet, Frédéric Franck, Jacques Rouanet

Eur J Dermatol· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dermatological manifestations in Costello syndrome: A prospective multicentric study of 31 HRAS-positive variant patients.
Didier Bessis, Anne-Claire Bursztejn, Fanny Morice-Picard, Yline Capri, Sébastien Barbarot, Jacques Rouanet

J Eur Acad Dermatol Venereol· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
CD38 Targeting in Aggressive, Treatment-Refractory Cutaneous T-Cell Lymphomas.
Van Anh Ta, Maxime Battistella, Lin Pierre Zhao, Gabor Dobos, Caroline Ram-Wolff, Jacques Rouanet

J Invest Dermatol· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Immune Checkpoint Inhibitor (ICI) Rechallenge in Advanced Melanoma Patients' Responders to a First Course of ICI: A Multicenter National Retrospective Study of the French Group of Skin Cancers (Groupe de Cancérologie Cutanée, GCC).
Charlée Nardin, Aymeric Hennemann, Kadiatou Diallo, Elisa Funck-Brentano, Eve Puzenat, Jacques Rouanet

Cancers (Basel)· July 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Metastatic melanoma treated by immunotherapy: discovering prognostic markers from radiomics analysis of pretreatment CT with feature selection and classification.
Gulnur Ungan, Anne-Flore Lavandier, Jacques Rouanet, Constance Hordonneau, Benoit Chauveau

Int J Comput Assist Radiol Surg· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Assessment of Tc-NTP 15-5 uptake on cartilage, a new proteoglycan tracer: Study protocol for a phase I trial (CARSPECT).
Emilie Thivat, Marion Chanchou, Sylvain Mathieu, Sophie Levesque, Tommy Billoux, Jacques Rouanet

Front Med (Lausanne)· October 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The Role of Surgery After Remission of Nonsystemic Extensive Periorbital Basal Cell Carcinoma Treated by Vismodegib: A Systematic Review.
Delphine Peillex, Léa Passemard, Benoit Magnin, Jacques Rouanet, Nathalie Pham Dang

Dermatol Surg· September 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Real-life Use of Bexarotene for T-cell Cutaneous Lymphoma Management: Efficacy and Tolerance with Low Doses.
Jacques Rouanet, Ines Joulie, Celine Lambert, Michel D'Incan

Acta Derm Venereol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
G
Gliptin-induced bullous pemphigoid: withdrawal of gliptin allows for faster control of the disease.
Méryll Prugnit-Rouanet, Stéphanie Delaumenie, Amélie Couraud, Damien Audevard, Jacques Rouanet

Eur J Dermatol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Positive Association Between Location of Melanoma, Ultraviolet Signature, Tumor Mutational Burden, and Response to Anti-PD-1 Therapy.
Léa Dousset, Florence Poizeau, Caroline Robert, Sandrine Mansard, Laurent Mortier, Jacques Rouanet

JCO Precis Oncol· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase I study of [I] ICF01012, a targeted radionuclide therapy, in metastatic melanoma: MELRIV-1 protocol.
Emilie Thivat, Jacques Rouanet, Philippe Auzeloux, Nicolas Sas, Elodie Jouberton

BMC Cancer· April 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Radioimmunotherapy in Oncology: Overview of the Last Decade Clinical Trials.
Aurélie Rondon, Jacques Rouanet, Françoise Degoul

Cancers (Basel)· November 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Benzamide derivative radiotracers targeting melanin for melanoma imaging and therapy: Preclinical/clinical development and combination with other treatments.
Jacques Rouanet, Mercedes Quintana, Philippe Auzeloux, Florent Cachin, Françoise Degoul

Pharmacol Ther· August 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
New insight into the role of ANXA1 in melanoma progression: involvement of stromal expression in dissemination.
Solène Delorme, Maud Privat, Nicolas Sonnier, Jacques Rouanet, Tiffany Witkowski

Am J Cancer Res· April 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of Targeted Radionuclide Therapy Using [I]ICF01012 in 3D Pigmented BRAF- and NRAS-Mutant Melanoma Models and In Vivo NRAS-Mutant Melanoma.
Hussein Akil, Mercedes Quintana, Jérémy H Raymond, Tommy Billoux, Valentin Benboubker, Jacques Rouanet

Cancers (Basel)· March 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Immune checkpoint inhibitors reverse tolerogenic mechanisms induced by melanoma targeted radionuclide therapy.
Jacques Rouanet, Valentin Benboubker, Hussein Akil, Ana Hennino, Philippe Auzeloux

Cancer Immunol Immunother· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
'
'Aberrant localisation of Annexin A1 is associated with metastatic outcome in thin melanomas'.
Pierre Romero, Zied Boudhraa, Matthieu Carton, Amr Hassan, Juliette Joubert-Zakeyh, Jacques Rouanet

Australas J Dermatol· May 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis